Clinical trials · California
Metastatic Prostate Cancer clinical trials in California
We’re tracking 165 recruiting metastatic prostate cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Comparing two drug combinations for advanced bladder cancer
This trial tests a new drug combination (Dato-DXd plus chemotherapy) against a standard chemotherapy combination for advanced bladder cancer that has spread or cannot be removed by surgery. It is for people whose cancer has grown after treatment with the drugs enfortumab vedotin (Padcev) and pembrolizumab (Keytruda).
Fullerton, CaliforniaAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Berkeley, CaliforniaAges 18 years+ - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Los Angeles, CaliforniaAges 18–100 - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Palo Alto, CaliforniaAges 18–100 - NCT04621435RecruitingPhase 1
PET imaging test for solid tumors using FAP-2286
This Phase 1 study tests a special imaging scan (using FAP-2286) to see solid tumors in people who have already been diagnosed. It may help doctors better detect where cancer is in the body and how to plan treatment.
San Francisco, CaliforniaAges 18 years+ - NCT05923684Recruiting
English prostate cancer visit feedback tool for shared decisions
This trial tests an English computer tool that gives feedback during prostate cancer treatment visits. It aims to help you and your clinician make more informed, shared decisions about next treatment steps.
Los Angeles, CaliforniaAges 18 years+ - NCT06084338RecruitingPhase 2
Focused Radiation Therapy Without Hormone Therapy for Advanced Prostate Cancer
This trial tests whether giving focused radiation to many cancer spots (SBRT) can work without using testosterone-blocking hormone therapy. It is for men whose prostate cancer has spread and is no longer responding to low testosterone, and who have already tried one of the newer hormone drugs.
West Los Angeles, CaliforniaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Santa Monica, CaliforniaAges 18–100 - NCT07210086RecruitingPhase 2
PET scans to guide radiation for limited metastatic prostate cancer
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Duarte, CaliforniaAges 18 years+ - NCT06101290Recruiting
Local therapy for progressing spots in genitourinary cancers
This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.
Sacramento, CaliforniaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Emeryville, CaliforniaAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+ - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Duarte, CaliforniaAges 18 years+ - NCT05694715RecruitingPhase 1
Test combo treatment for cancers with DNA repair gene mutations
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
San Francisco, CaliforniaAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06399419RecruitingPhase 1
Study of CBM588 with immunotherapy for advanced kidney cancer
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
Duarte, CaliforniaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Clovis, CaliforniaAges 18 years+ - NCT04883671Recruiting
SBRT to treat a few spots of adenoid cystic cancer
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
San Francisco, CaliforniaAges 18 years+ - NCT05333458RecruitingPhase 2
Atezolizumab plus selinexor for advanced alveolar soft tissue sarcoma
This Phase 2 trial tests whether combining atezolizumab with selinexor can slow or shrink advanced alveolar soft part sarcoma (ASPS) in people age 12 and older. It may help by improving the immune system’s ability to fight the cancer and stopping cancer cell growth signals.
Los Angeles, CaliforniaAges 12 years+
Metastatic Prostate Cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- City of Hope Comprehensive Cancer Center · 5 studies
- Stanford University · 4 studies
- University of California, San Francisco · 3 studies
- Alta Bates Summit Medical Center · 2 studies
- City of Hope · 2 studies
- Research Site · 2 studies
- Sansum Clinic · 2 studies
- USC / Norris Comprehensive Cancer Center · 2 studies
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Prostate Cancer trials in other states
Common questions
- Are there metastatic prostate cancer clinical trials in California?
- Yes. We're currently tracking 165 recruiting metastatic prostate cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.